

Click-to-Release-based Cryptophycin Drug Conjugates

Jona Voss¹, Peter Bitsch², Cedric Dessin¹, Harald Kolmar², and Norbert Sewald¹


¹ Organic and Bioorganic Chemistry, Faculty of Chemistry, Bielefeld University, Germany.

² Clemens-Schöpf Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Germany.

Contact: jona.voss@uni-bielefeld.de

Click-to-Release


- Traceless bioconjugation method for release of tetrazine-carbamate-bound payloads^[1]
- Release by deliberate administration of an activator (strained alkene, e.g. *trans*-cyclooctene (TCO))
- Established by Robillard *et al.* in 2013 with a proof of concept in 2016 (Doxorubicin release)^[2]




- Bioorthogonality through inverse electron-demand Diels-Alder reaction (iEDDA)
 - High stability and selective formation of pyridazine-click-product
 - Irreversibility through N₂ and concomitant CO₂ release
- Fast release kinetics ($k_2 = 1 - 10^6 \text{ M}^{-1}$)^[3]
- Non-internalising antibodies as homing devices allow extracellular receptors as targets

in vitro Release


- In vitro study of release upon TCO addition (pH = 7.4, NH₄OAc buffer / MeCN, c₀ = 0.15 mM)
- Maximum "release yield" after 24 h (64%)



Synthesis of Cryptophycin-Linkers




- Highly cytotoxic, usually in the pM range, even against multi-drug-resistant cell-lines^[4]
- Modifications in unit D superior to retain high cytotoxicity^[5]




- Synthesis of two conjugable tetrazine-carbamate-bound cryptophycins **9** and **15**

- Orthogonal click-reactivity of linker **15** (SPAAC at DBCO vs. iEDDA at tetrazine)




Payload: Cryptophycin-unit D [Dap(Me)]

	IC ₅₀ [pM]
KB-3-1	8.71
KB-V1	21·10 ³ (MDR+)
A-549	21.7
A-431	160




- Cysteine-addressable by Michael addition




- Azide-addressable by SPAAC

Antibody-Drug Conjugates




Trastuzumab-based ADCs




- Anti-Her2 mAb conjugated by Michael addition of Cryptophycin-Linker **9** to native cysteines
- Efficient cell-killing of medium and high Her2-expressing cell lines with pM IC₅₀ values
- TCO activation only efficient for RT112 cells: proteolysis competing with internalization?

Sibrotuzumab-based ADCs



- Non-internalising mAb targeting cancer-associated fibroblasts (CAFs), conjugated to Cryptophycin-Linker **9** (with engineered cysteines)
- Efficient killing of FAP(+) cells with pM efficacy but no adverse effects against FAP(-) cells
- Increased toxicity (x10) after washout and activation with TCO

Dextramab^[6]



For more Cryptophycin and Drug Conjugate research, please visit Jan-Niklas Bollnow (P1.210), Dominic Seifens Schmidt (P1.215) and Ninive Cati (P1.209).

Further Info

Reference

- R. M. Versteegen, R. Rossin, W. ten Hoeve, H. M. Janssen, M. S. Robillard, *Angew. Chem. Int. Ed.* **2013**, *52*, 14112.
- R. Rossin, S. M. J. van Duijnhoven, W. ten Hoeve, H. M. Janssen, L. H. J. Kleijn, F. J. M. Hoeben, R. M. Versteegen, M. S. Robillard, *Bioconjug. Chem.* **2016**, *27*, 1697.
- B. L. Oliveira, Z. Guo, G. J. L. Bernardes, *Chem. Soc. Rev.* **2017**, *46*, 4895.
- C. Weiss, E. Figueras, A. N. Borbély and N. Sewald, *J. Pept. Sci.* **2017**, *23*, 514.
- C. Dessin, T. Schachtsiek, G. Blanchard Nerin, N. Sewald, International Patent WO2022//175222, Bielefeld University, Bielefeld, **2022**.
- H. Schneider, L. Deweid, T. Pirzer, D. Yanakieva, S. Englert, B. Becker, O. Avrutina, H. Kolmar, *ChemistryOpen* **2019**, *8*, 354.

